---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-316607"
form_type: "8-K"
ticker: null
cik: "0001697532"
company_name: "Applied Therapeutics, Inc."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:21:59.292851+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Applied Therapeutics to be acquired by Cycle Group for $0.088/share plus CVRs worth up to $0.40

## Summary
- Offer price: $0.088 per share cash plus one non-tradeable CVR with up to $0.40 per share in milestone payments.
- Milestones include FDA approval for galactosemia ($0.10), CMT-SORD ($0.10), and net sales >= $200M ($0.20).
- Parent provides up to $8.5M unsecured promissory note at 24% interest to fund working capital pending close.
- Board unanimously approved; transaction subject to tender of majority of shares and other customary conditions.
- Termination fee of $648,000 plus 4.5% of outstanding note principal payable by Applied in certain circumstances.

## SEC filing metadata
- accession: 0001193125-25-316607
- form_type: 8-K
- cik: 0001697532
- company_name: Applied Therapeutics, Inc.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1697532/000119312525316607/0001193125-25-316607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1697532/000119312525316607/d41524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-316607
- JSON: https://secwatch.observer/filing/0001193125-25-316607.json
- Plain text: https://secwatch.observer/filing/0001193125-25-316607.txt

## Key facts
- Debt Financings
  Applied Therapeutics, Inc. incurred loan of not fully specified in excerpt with not fully specified in excerpt at not fully specified in excerpt maturing not fully specified in excerpt.
  - Instrument: loan
  - Principal: not fully specified in excerpt
  - Counterparty: not fully specified in excerpt
  - Rate: not fully specified in excerpt
  - Maturity: not fully specified in excerpt
  - Event: incurrence
  source text: Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this report under the caption titled “Unsecured Promissory Note,” including Exhibit 10.1 attached hereto, is incorporated by reference in this Item 2.03.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1697532/000119312525316607/0001193125-25-316607-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.